{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=15",
    "query": {
      "intervention": "Placebo Administration first",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 1736,
    "total_pages": 174,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Administration+first&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T12:55:19.615Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02548728",
      "title": "Oxytocin Treatment of Opioid Dependence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Opioid Dependence",
        "Opioid Withdrawal"
      ],
      "interventions": [
        {
          "name": "Intranasal Oxytocin Spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 12,
      "start_date": "2016-02",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-07",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02548728"
    },
    {
      "nct_id": "NCT03657095",
      "title": "A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Esuberaprost",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lung Biotechnology PBC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 112,
      "start_date": "2018-12-10",
      "completion_date": "2019-07-20",
      "has_results": true,
      "last_update_posted_date": "2020-09-07",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657095"
    },
    {
      "nct_id": "NCT01793051",
      "title": "Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloma"
      ],
      "interventions": [
        {
          "name": "Minocycline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2013-03-22",
      "completion_date": "2020-09-18",
      "has_results": true,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01793051"
    },
    {
      "nct_id": "NCT03757325",
      "title": "Study to Evaluate DNL747 in Subjects With Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "DNL747",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Denali Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 16,
      "start_date": "2019-02-13",
      "completion_date": "2019-12-05",
      "has_results": false,
      "last_update_posted_date": "2020-02-26",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Orlando, Florida • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03757325"
    },
    {
      "nct_id": "NCT00463385",
      "title": "A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis With Myeloid Metaplasia",
        "Myeloid Metaplasia",
        "Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo to pomalidomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo to prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2007-04-01",
      "completion_date": "2013-12-31",
      "has_results": true,
      "last_update_posted_date": "2019-11-20",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00463385"
    },
    {
      "nct_id": "NCT06750289",
      "title": "Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Asthma"
      ],
      "interventions": [
        {
          "name": "ICS-LABA",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "benralizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo for Benralizumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 130,
      "start_date": "2025-03-28",
      "completion_date": "2026-09-21",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 20,
      "location_summary": "Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06750289"
    },
    {
      "nct_id": "NCT02287038",
      "title": "Atomoxetine in Veterans With Comorbid ADHD/PTSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Post Traumatic Stress Disorder",
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Atomoxetine 80 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "20 Years to 60 Years"
      },
      "enrollment_count": 44,
      "start_date": "2014-10-15",
      "completion_date": "2017-04-14",
      "has_results": true,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02287038"
    },
    {
      "nct_id": "NCT02119416",
      "title": "Gender Difference in Response to Caffeine in Children and Adolescents",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Placebo Administration first",
          "type": "DRUG"
        },
        {
          "name": "Low Caffeine Administration first (1mg/kg body weight)",
          "type": "DRUG"
        },
        {
          "name": "High Caffeine Administration first (2mg/kg body weight)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "State University of New York at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 101,
      "start_date": "2011-08",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2022-08-17",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02119416"
    },
    {
      "nct_id": "NCT03617458",
      "title": "Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Artery Hypertension"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "mHealth Intervention",
          "type": "DEVICE"
        },
        {
          "name": "Usual Care",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2018-08-23",
      "completion_date": "2025-08-19",
      "has_results": true,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 1,
      "location_summary": "Nashvile, Tennessee",
      "locations": [
        {
          "city": "Nashvile",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03617458"
    },
    {
      "nct_id": "NCT03322540",
      "title": "Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Epacadostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 154,
      "start_date": "2017-12-15",
      "completion_date": "2020-11-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-22",
      "last_synced_at": "2026-11-15T12:55:19.615Z",
      "location_count": 15,
      "location_summary": "Anaheim, California • Whittier, California • Fort Myers, Florida + 12 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03322540"
    }
  ]
}